Bosentan is surely an inducer of CYP3A and CYP2C9. For that reason plasma concentrations of prescription drugs metabolized by both of these isozymes will be lessened when bosentan is coadministered. There are many prospective confounders, eg, Continual adaptation, symptom exacerbation by co-morbid circumstances like lung fibrosis and anemia. It's difficult https://judahixjvg.blogdosaga.com/26023199/getting-my-bosentan-to-work